Spacecraft captures solar eclipse from the moon
(dpa) - The lunar lander Blue Ghost experienced a total solar eclipse on the moon overnight, while a lunar eclipse was visible from some places on Earth.
Cameras on the Blue Ghost, built by Texas-based company Firefly Aerospace, recorded the Earth moving in front of the Sun across the lunar horizon and obscuring it, sending images back to Earth.
The two-metre-long spacecraft landed on the Moon in early March in the Mare Crisium, an area with a diameter of about 500 kilometres. It is currently examining the Moon with scientific instruments until Sunday.
The mission, called "Ghost Riders in the Sky,", is the first lunar mission for Firefly Aerospace, which had previously mainly developed launchers.
It's not the first time a device has captured a solar eclipse from another celestial body. In 1967, the "Surveyor 3" lunar mission took numerous pictures of the Earth as it moved in front of the Sun.
Two years later, the crew of Apollo 12 witnessed the same on their return from the Moon.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
A Cracked Piece of Metal Self-Healed in Experiment That Stunned Scientists
File this under 'That's not supposed to happen!'. In an experiment published in 2023, scientists observed a damaged section of metal healing itself. Though the repair was only on a nanoscale level, understanding the physics behind the process could inspire a whole new era of engineering. A team from Sandia National Laboratories and Texas A&M University was testing the resilience of a small piece of platinum suspended in a vacuum using a specialized transmission electron microscope technique to pull the ends of the metal 200 times every second. They then observed the self-healing at ultra-small scales in the 40-nanometer-thick wafer of metal. Cracks caused by the kind of strain described above are known as fatigue damage: repeated stress and motion that causes microscopic breaks, eventually causing machines or structures to break. Amazingly, after about 40 minutes of observation, the crack in the platinum started to fuse back together and mend itself before starting again in a different direction. "This was absolutely stunning to watch first-hand," said materials scientist Brad Boyce from Sandia National Laboratories when the results were announced. "We certainly weren't looking for it. What we have confirmed is that metals have their own intrinsic, natural ability to heal themselves, at least in the case of fatigue damage at the nanoscale." These are exact conditions, and we don't know yet exactly how this is happening or how we can use it. However, if you think about the costs and effort required for repairing everything from bridges to engines to phones, there's no telling how much difference self-healing metals could make. While the observation is unprecedented, it's not wholly unexpected. In 2013, Texas A&M University materials scientist Michael Demkowicz worked on a study predicting that this kind of nanocrack healing could happen, driven by the tiny crystalline grains inside metals essentially shifting their boundaries in response to stress. Demkowicz also worked on this study, using updated computer models to show that his decade-old theories about metal's self-healing behavior at the nanoscale matched what was happening here. That the automatic mending process happened at room temperature is another promising aspect of the research. Metal usually requires lots of heat to shift its form, but the experiment was carried out in a vacuum; it remains to be seen whether the same process will happen in conventional metals in a typical environment. A possible explanation involves a process known as cold welding, which occurs under ambient temperatures whenever metal surfaces come close enough together for their respective atoms to tangle together. Typically, thin layers of air or contaminants interfere with the process; in environments like the vacuum of space, pure metals can be forced close enough together to literally stick. "My hope is that this finding will encourage materials researchers to consider that, under the right circumstances, materials can do things we never expected," said Demkowicz. The research was published in Nature. An earlier version of this article was published in July 2023. A Fifth Force of Nature May Have Been Discovered Inside Atoms Strange Radio Signals Detected Emanating From Deep Under Antarctic Ice Light Squeezed Out of Darkness in Surprising Quantum Simulation
Yahoo
6 hours ago
- Yahoo
Conspiracy Theorists Are Creating Special AIs to Agree With Their Bizarre Delusions
Conspiracy theorists are using AI chatbots not only to convince themselves of their harebrained beliefs, but to recruit other users on social media. As independent Australian news site Crikey reports, conspiracy theorists are having extensive conversations with AI chatbots to "prove" their beliefs. Then, they post the transcripts and videos on social media as "proof" to others. According to the outlet's fascinating reporting, there are already several bots specifically trained on harebrained conspiracy theories, including a custom bot designed to convince parents not to vaccinate their children. The news highlights a troubling trend, with countless ChatGPT users developing bizarre delusions and even spiraling into severe mental health crises, as we reported last week. Experts have warned that AI chatbots are designed to be incredibly sycophantic, predisposing them to agreeing with users even when doing so is clearly harmful. Much like delusions of spiritual awakenings, messianic complexes, and boundless paranoia, conspiracy theorists are finding the perfect conversational partner in tools like ChatGPT. Since they were trained on the open web — an enormous data set that includes unfounded conspiracy theories, like the belief that vaccines cause autism — they can easily be coaxed into furthering these theories. As Crikey reports, one chatbot called Neo-LLM was trained by a Texan anti-vaxxer using over 100,000 dubious articles from the far-right conspiracy theory news website Natural News. It's unclear how many users have downloaded the chatbot, but promotional videos have garnered tens of thousands of views. In short, it's an alarming trend that shows the dangers of powerful AI chatbot tech falling into the wrong hands. In particular, people suffering from mental health issues can be convinced they're talking to a real authority, rather than a parroting language model that continuously calculates the probability of the next word. That kind of delusion can have devastating consequences. As the New York Times reported last week, a 35-year-old man — who had previously been diagnosed with bipolar disorder and schizophrenia before becoming obsessed with ChatGPT — was shot and killed by police after he charged at them with a knife following a mental health crisis centering on the bot. Since AI chatbots have become incredibly effective at generating convincing-sounding answers, their ill use could have real-life implications. Researchers have shown that AI chatbots can easily be weaponized and taught how to spew an endless firehose of disinformation. With the Trump administration actively rolling back AI regulations and key politicians furthering anti-vaccine conspiracy theories themselves, the future looks bleak. Even tech companies have historically failed to implement effective guardrails to stop chatbots from hallucinating. However, some experts have pondered if the tech could be used for good as well. Last year, researchers at MIT found that chatbots can also be used to reduce the belief in conspiracy theories, a glimmer of hope as the internet becomes increasingly polluted with deranged, AI-generated claims. More on AI delusions: People Are Becoming Obsessed with ChatGPT and Spiraling Into Severe Delusions
Yahoo
16 hours ago
- Yahoo
If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This
Cathie Wood, founder, CEO and chief investment officer of Ark Invest, continues to make headlines for her high-conviction approach to disruptive innovation. Her flagship fund, the Ark Innovation ETF (ARKK), has posted a 52.9% return in the past 52 weeks, reflecting investor confidence. Known for identifying transformational themes early, Wood maintains focused exposure to industries like genomics, autonomous technology, and blockchain. Within this context, Natera (NTRA) has drawn sharp relevance. The company leads in cell-free DNA testing and precision medicine, aligning directly with Ark's long-term thesis. CoreWeave Just Revealed the Largest-Ever Nvidia Blackwell GPU Cluster. Should You Buy CRWV Stock? AMD Is Gunning for Nvidia's AI Chip Throne. Should You Buy AMD Stock Now? The Saturday Spread: Statistical Signals Flash Green for CMG, TMUS and VALE Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For investors seeking a stock that fits the Ark playbook, Natera may represent one of the most fundamentally aligned additions under Wood's current investment lens. Based in Austin, Texas, stands Natera (NTRA), a pioneer in the field of cell-free DNA and genetic testing. The $23.3 billion biotech firm's arsenal includes powerful offerings like Panorama for prenatal screening, Signatera for real-time cancer surveillance, and Prospera, which sharpens the lens on transplant rejection. Over the last three months, the stock has climbed 16.9%, leaving the broader S&P 500 Index's ($SPX) 5.4% gain behind. On May 8, Natera opened the books on its first-quarter, and the results exceeded Wall Street expectations. Investors responded swiftly, with the stock inching up 1.5% the same day. Natera posted $501.8 million in total revenues, a 36.5% year-over-year increase that soared past Wall Street's $443.3 million forecast. Behind those numbers were powerhouse operations. The company processed 855,100 tests during the quarter, up 16.2% year over year. Women's health volumes climbed meaningfully over the fourth quarter, but it was Signatera that stole the spotlight. The personalized, tumor-informed molecular residual disease test reached new heights, recording its highest volume quarter ever. Clinical volumes for Signatera grew 52% year over year, with a sequential gain of roughly 16,005 units over Q4, marking the most significant quarter-on-quarter growth to date. Gross margins landed at 63.1%, reflecting solid cost discipline. Moreover, Natera's net loss narrowed 1% from the year-ago period to $66.9 million. Also, the company managed to trim its loss per share by 10.7% to $0.50, outperforming analysts' projections of a $0.59 loss per share. As for liquidity, the balance sheet remained in good shape. Cash, cash equivalents and restricted cash climbed to $973.8 million, up from $945.6 million on Dec 31, 2024. CEO Steve Chapman has made no secret of the firm's long-term vision. He believes Signatera could ultimately generate over $5 billion in annual revenue, and he emphasized that they are still playing in the shallow end of a much deeper market pool. In a move that reinforced this optimism, Natera has raised its full-year revenue guidance to between $1.94 billion and $2.02 billion. That is a $70 million boost from the midpoint of its earlier outlook, pointing to a 26% year-over-year growth. On the other hand, analysts expect the Q2 2025 loss per share to widen 100% year over year to $0.60. For FY25, the loss per share is projected to increase 37% to $2.10, but FY26 could bring relief, with a forecast 64.8% narrowing to $0.74, hinting that profitability may finally be within reach. Analysts seem to be singing in harmony when it comes to NTRA, marking it with a firm 'Strong Buy' rating. Out of 19 analysts following the stock, 16 have given it an enthusiastic 'Strong Buy' rating, and the remaining three have placed their bets on a 'Moderate Buy.' The average price target of $200.42 represents potential upside of 17.6%. Meanwhile, the Street-High target of $251 hints at a 48% climb from current levels. Such projections do not come lightly and often reflect deep-rooted confidence in future earnings momentum and strategic execution. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
